Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I believe these fears are overblown given PFE's oncology portfolio, Eliquis, and tafamidis franchise, which delivered strong Q3 performance.